Alzheimer’s disease master regulators analysis: search for potential molecular targets and drug repositioning candidates

Abstract

BackgroundAlzheimer’s disease (AD) is a multifactorial and complex neuropathology that involves impairment of many intricate molecular mechanisms. Despite recent advances, AD pathophysiological characterization remains incomplete, which hampers the development of effective treatments. In fact, currently, there are no effective pharmacological treatments for AD. Integrative strategies such as transcription regulatory network and master regulator analyses exemplify promising new approaches to study complex diseases and may help in the identification of potential pharmacological targets.MethodsIn this study, we used transcription regulatory network and master regulator analyses on transcriptomic data of human hippocampus to identify transcription factors (TFs) that can potentially act as master regulators in AD. All expression profiles were obtained from the Gene Expression Omnibus database using the GEOquery package. A normal hippocampus transcription factor-centered regulatory network was reconstructed using the ARACNe algorithm. Master regulator analysis and two-tail gene set enrichment analysis were employed to evaluate the inferred regulatory units in AD case-control studies. Finally, we used a connectivity map adaptation to prospect new potential therapeutic interventions by drug repurposing.ResultsWe identified TFs with already reported involvement in AD, such as ATF2 and PARK2, as well as possible new targets for future investigations, such as CNOT7, CSRNP2, SLC30A9, and TSC22D1. Furthermore, Connectivity Map Analysis adaptation suggested the repositioning of six FDA-approved drugs that can potentially modulate master regulator candidate regulatory units (Cefuroxime, Cyproterone, Dydrogesterone, Metrizamide, Trimethadione, and Vorinostat).ConclusionsUsing a transcription factor-centered regulatory network reconstruction we were able to identify several potential molecular targets and six drug candidates for repositioning in AD. Our study provides further support for the use of bioinformatics tools as exploratory strategies in neurodegenerative diseases research, and also provides new perspectives on molecular targets and drug therapies for future investigation and validation in AD.Electronic supplementary materialThe online version of this article (10.1186/s13195-018-0394-7) contains supplementary material, which is available to authorized users.

Meta-analysis of mouse transcriptomic studies supports a context-dependent astrocyte reaction in acute CNS injury versus neurodegeneration

“…Nuclear receptor subfamily 4 group A member 3 has been involved in Lewy body disease and multiple system atrophy [86]. TSC22D1 is a pro-apoptotic tumor suppressor transcription factor induced by transforming growth factor β (TGFβ), that was found as putatively involved in AD pathophysiology in an unbiased network analysis of transcription factors and their targets [87] and was also present in our acute injury-DOWN signature. The presence of App (encoding the amyloid β precursor protein or AβPP) in the neurodegeneration-UP signature is intriguing and cannot just be explained by a leakage of the APP transgene expression to astrocytes in AβPP-overexpressing AD mouse models [88], because it was also notably upregulated in other mouse models such as SOD1-G93A ALS mice.…”

Hippocampal CA1 βCaMKII mediates neuroinflammatory responses via COX-2/PGE2 signaling pathways in depression

“…Recent studies have indicated that the p38 MAPK/ATF-2 signaling pathway induces COX-2-derived PGE2 production during inflammatory responses in brain injury and in inflammatory diseases [ 41 ]. Accordingly, ATF-2 may potentially function as a critical molecular target for drug therapies in neurodegenerative diseases [ 42 ]. Taken together, our data demonstrate that a Ca 2+ -dependent βCaMΚΙΙ response appears to provide a bridge between stress exposure and neuroinflammatory activation.…”

Integrated DNA methylation analysis reveals a potential role for ANKRD30B in Williams syndrome

“…The ELMER analysis exploits the interplay between DNA methylation and transcription factor binding at distal regulatory sites to identify potential master regulator transcription factors that may help explain how microdeletion has such widespread functional consequences. Therefore, identifying master regulator transcription factors provides insight into complex biological outcomes through the regulation of multiple genes, and these transcription factors could serve as targets for the development of novel therapeutic approaches [ 38 ]. Through ELMER analysis, we identified BCL11A as a potential upstream master regulator transcription factor.…”